Alnylam Pharmaceuticals Announces Management Transition Plan in Business Development; Senior Vice President Leaves

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that Vincent Miles, Ph.D., Senior Vice President, Business Development, is planning to leave the company to pursue his interests in other areas. He will remain with Alnylam on a full-time basis through the end of the year and will then work through a transition period as the company identifies a replacement. After almost thirty years of employment in the biotechnology industry, including leadership roles in a variety of functional areas at Amersham International, Pharmacia Biotech, Millennium Pharmaceuticals, and Alnylam, Dr. Miles plans to explore new opportunities beyond business development. Barry Greene, Chief Operating Officer of Alnylam, will expand his active involvement in and assume leadership responsibilities for all business development efforts, including ongoing pharmaceutical partnership discussions and InterfeRx™ licensing activities.

>>> Discuss This Story

MORE ON THIS TOPIC